US · QGEN · MEDICAL - DIAGNOSTICS & RESEARCH
Qiagen N.V. (QGEN) intrinsic value and stock valuation
$49.30as of 2026-11-21 · Mkt cap 8.72B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Qiagen N.V. DCF and intrinsic value
InvestorsCraft values QGEN with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from QGEN’s statements →
Qiagen N.V. Graham Number
Graham Number: $28.90d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Baxter International Inc. (BAX) $25.39
- Exelixis, Inc. (EXEL) $64.63
- Charles River Laboratories International, Inc. (CRL) $314.32
- Revvity, Inc. (RVTY) $145.22
- ICON Public Limited Company (ICLR) $186.71
- Align Technology, Inc. (ALGN) $155.17
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- Bio-Techne Corporation (TECH) $72.67
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Operating income | $520.3M | $97.7M | $409.9M | $531.5M | $630.1M |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| EPSd | $2.04M | $382.6K | $1.57M | $1.9M | $2.28M |
| Operating cash flow | $654.3M | $673.6M | $459.5M | $715.3M | $639M |
| Capital expenditure | -$-201.05M | -$-167.17M | -$-162.8M | -$-149.34M | -$-206.53M |
| Free cash flow | $453.3M | $506.4M | $296.7M | $565.9M | $432.5M |
| Total assets | $6.3B | $5.69B | $6.12B | $6.29B | $6.15B |
| Total debt | $1.65B | $1.61B | $1.69B | $2.03B | $2.12B |
| Net debt | $815.4M | $945.6M | $1.02B | $1.3B | $1.24B |
| Total equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.1B |
| Cash and short-term investments | $1.1B | $1.15B | $1.06B | $1.42B | $1.07B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Cost of revenue | $798.5M | $1.01B | $731.6M | $757M | $800.8M |
| Gross profit | $1.29B | $967.4M | $1.23B | $1.38B | $1.45B |
| Research and development expenses | $187.5M | $193.5M | $198.5M | $189.9M | $190M |
| Selling, general and administrative expenses | $583.7M | $564.4M | $579.2M | $604M | $584.5M |
| Other expenses | $0.00 | $111.8M | $46.1M | $59.3M | $46.3M |
| Operating expenses | $771.2M | $869.6M | $823.8M | $853.1M | $820.7M |
| Cost and expenses | $1.57B | $1.88B | $1.56B | $1.61B | $1.62B |
| Interest income | $64.3M | $68M | $79M | $32.8M | $9.55M |
| Interest expense | $33.3M | $43.8M | $53.4M | $58.4M | $54.5M |
| Depreciation and amortization | $193.8M | $203.3M | $205.3M | $208.4M | $214.9M |
| Ebitda | $717.3M | $368.3M | $688.6M | $779.4M | $895.2M |
| Operating income | $520.3M | $97.7M | $409.9M | $531.5M | $630.1M |
| Total other income/expenses, net | -$-30.04M | $23.4M | $19.9M | -$-18.86M | -$-4.25M |
| Income before tax | $490.3M | $121.2M | $429.8M | $512.6M | $625.8M |
| Income tax expense | $65.4M | $37.6M | $88.5M | $89.4M | $113.2M |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| Weighted average shares outstanding | $207.9M | $216.4M | $217.5M | $220.8M | $221.1M |
| Weighted average diluted shares outstanding | $207.9M | $218.5M | $217.5M | $223.2M | $225.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.1B | $1.15B | $1.06B | $1.42B | $1.07B |
| Net receivables | $402.6M | $459M | $515.6M | $434.1M | $469.7M |
| Inventory | $301.9M | $279.3M | $398.4M | $358M | $327.5M |
| Total current assets | $2B | $1.96B | $2.15B | $2.39B | $2.11B |
| Property, plant and equipment, net | $924M | $753.6M | $765M | $662.2M | $638.2M |
| Goodwill and intangible assets | $3.09B | $2.73B | $3B | $2.9B | $2.98B |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $4.3B | $3.73B | $3.97B | $3.89B | $4.04B |
| Total assets | $6.3B | $5.69B | $6.12B | $6.29B | $6.15B |
| Accounts payable | $72.7M | $83.3M | $84.2M | $98.7M | $101.2M |
| Short-term debt | $0.00 | $77.8M | $610.2M | $411.8M | $869.7M |
| Deferred revenue | $0.00 | $70.8M | $66.4M | $69M | $63.4M |
| Total current liabilities | $512.1M | $543.6M | $1.08B | $974.5M | $1.52B |
| Long-term debt | $1.65B | $1.53B | $1.08B | $1.61B | $1.25B |
| Deferred revenue, non-current | $0.00 | $18M | $15.7M | $15.2M | $11.3M |
| Total non-current liabilities | $2.01B | $1.58B | $1.23B | $1.85B | $1.53B |
| Capital lease obligations | $0.00 | $121M | $101.3M | $93.6M | $98.6M |
| Total liabilities | $2.52B | $2.12B | $2.31B | $2.82B | $3.05B |
| Common stock | $2.53M | $2.6M | $2.7M | $2.7M | $2.7M |
| Retained earnings | $2.75B | $2.45B | $2.46B | $2.16B | $1.79B |
| Accumulated other comprehensive income (loss) | -$-377.31M | -$-474.54M | -$-433.83M | -$-404.09M | -$-326.67M |
| Total equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.1B |
| Total investments | $259.9M | $489.4M | $389.7M | $687.6M | $184.8M |
| Total debt | $1.65B | $1.61B | $1.69B | $2.03B | $2.12B |
| Net debt | $815.4M | $945.6M | $1.02B | $1.3B | $1.24B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| Depreciation and amortization | $193.8M | $203.3M | $205.3M | $208.4M | $214.9M |
| Stock-based compensation | $50.4M | $43.6M | $47.1M | $49.5M | $38.4M |
| Change in working capital | -$-34.51M | $135.5M | -$-186.96M | -$-31.88M | -$-130.01M |
| Accounts receivable | -$-36.39M | $12.2M | -$-55.12M | $15.5M | -$-7.4M |
| Inventory | -$-850K | $87.8M | -$-44.79M | -$-61.95M | -$-81.8M |
| Accounts payable | -$-8.42M | $1.45M | -$-22.42M | -$-1.76M | -$-5.97M |
| Net cash provided by operating activities | $654.3M | $673.6M | $459.5M | $715.3M | $639M |
| Investments in property, plant and equipment | -$-207.13M | -$-167.17M | -$-162.8M | -$-149.34M | -$-206.53M |
| Acquisitions, net | -$-291.23M | $0.00 | -$-149.53M | -$-63.65M | -$-16.63M |
| Net cash used for investing activities | -$-305.28M | -$-249.23M | -$-87.66M | -$-726.76M | -$-202.43M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $7.92M |
| Common stock repurchased | -$-307.36M | -$-292.1M | -$-17.68M | -$-25.36M | -$-99.99M |
| Dividends paid | -$-54.24M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-178.98M | -$-422.9M | -$-433.83M | -$-125.8M | -$-150.37M |
| Net change in cash | $175.5M | -$-4.53M | -$-62.59M | -$-149.85M | $282.5M |
| Cash at end of period | $839M | $663.6M | $668.1M | $730.7M | $880.5M |
| Operating cash flow | $654.3M | $673.6M | $459.5M | $715.3M | $639M |
| Capital expenditure | -$-201.05M | -$-167.17M | -$-162.8M | -$-149.34M | -$-206.53M |
| Free cash flow | $453.3M | $506.4M | $296.7M | $565.9M | $432.5M |
Line items
Line items
Line items
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
- CEO
- Thierry Bernard
- Employees
- 5.65K
- Beta
- 0.64
Explore
Frequently asked questions
What is the intrinsic value of Qiagen N.V. (QGEN)?
Qiagen N.V. (QGEN) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is QGEN undervalued?
QGEN trades at a price of $49.30 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.